Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y₁₂ Inhibitor Prescribing After Percutaneous Coronary Intervention.

ABSTRACT: Black patients suffer worse outcomes after percutaneous coronary intervention (PCI) than White patients. Inequities in antiplatelet prescribing may contribute to this health disparity. We compared P2Y₁₂ inhibitor prescribing by race following CYP2C19 genotyping to guide antiplatelet therapy selection after PCI. Patients from 9 sites that performed clinical CYP2C19 genotyping after PCI were included. Alternative therapy (e.g., prasugrel or ticagrelor) was recommended for CYP2C19 no-function allele carriers, in whom clopidogrel is predicted to be less effective. The primary outcome was choice of P2Y₁₂ inhibitor (clopidogrel vs. alternative therapy) based on genotype. Of 3,342 patients included, 2,448 (73%) were White, and 659 (20%) were Black. More Black than White pati

SUBMITTER: Cavallari LH 

PROVIDER: S-EPMC9957848 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature